B
ecause of increased antimicrobial resistance and a shortage of novel antimicrobial development, new dosing strategies have been proposed to optimize the pharmacodynamics of existing antimicrobials. The application of pharmacodynamic principles can aid in the preservation of antibiotic efficacy, impede the emergence of resistance, and potentially provide a pharmacoeconomic benefit. 1 A-Lactams are time-dependent killing antibiotics and demonstrate maximum efficacy when the percentage of time during which the free drug concentration exceeds the minimum inhibitory concentration (%f T 9 MIC) is optimized. In general, a bactericidal effect occurs when the free drug concentration exceeds the MIC for 40%, 50%, and 60% to 70% of the dosing interval for the carbapenems, penicillins, and cephalosporins, respectively. 2, 3 Piperacillin-tazobactam and meropenem both exhibit time-dependent killing and are often used in the treatment of multidrug-resistant bacterial infections. 1, 2, 4 Prolonged infusions of these A-lactams increase the time of antimicrobial exposure above the MIC and should as a result improve their efficacy.
1,2,4Y6
Population pharmacokinetic modeling and Monte Carlo simulations have been used to generate new dosing strategies, such as the prolonged infusion of A-lactam antibiotics, and have been applied directly into clinical practice. 4 Piperacillintazobactam as a prolonged infusion of 3.375 g in Monte Carlo simulations demonstrates a greater probability of attaining 50% f T 9 MIC in isolates of reduced susceptibility and has corresponded to improved outcomes in critically ill patients. 2, 4 The pharmacodynamic profile of meropenem has been evaluated as a prolonged infusion administration. 6 Although less outcome data in the literature are available for meropenem use with this dosing strategy, prolonged infusions of meropenem have greater %f T 9 MIC and potentially reduced morbidity and mortality compared with standard infusions. 7 Based on the above evidence, the University of Wisconsin Hospital and Clinics instituted a guideline that was approved by the Pharmacy and Therapeutics Committee for the prolonged infusions of both piperacillin-tazobactam and meropenem for patients receiving this therapy in a medical and surgical intensive care unit (ICU), on August 1, 2008. This study was conducted after the guideline was instituted to further evaluate the efficacy of prolonged infusion regimens. The objective of our study was to compare the clinical and pharmacoeconomic outcomes of conventional intermittent dosing of piperacillin-tazobactam and meropenem to the prolonged infusions in critically ill patients, with a proactive focus on reducing ventilator days in ventilated patients, length of stay in both the ICU and hospital, and patient mortality.
MATERIALS AND METHODS
This study was approved by the University of Wisconsin Hospital and Clinics Health Sciences institutional review board. Data were collected by conducting a retrospective chart review of all patients 18 to 89 years of age admitted to the medical and surgical ICU who received at least 72 hours of therapy with piperacillin-tazobactam or meropenem from February 1, 2008, to January 31, 2009. Cystic fibrosis patients, those receiving continuous renal replacement therapy, or those who were receiving therapy in the ICU from July 31 to August 1 and had their regimen changed per the new protocol were excluded. The first dose of each antibiotic is infused over 30 minutes to rapidly obtain therapeutic concentrations. Each subsequent dose is given per prolonged infusion while the patient is in the ICU. According to the guideline, a patient's regimen may change when transferred out of this ICU. For patients with a pathogen with an MIC of 2 Hg/mL or greater, the same dosage, interval, and infusion rate continued on the intermediate care or general care unit for both piperacillin-tazobactam and meropenem. For those pathogens with MICs of less than 2 Hg/mL, or if there is no recovered organism, the piperacillin-tazobactam or meropenem regimen is changed to intermittent infusion dosing and is adjusted based on renal function upon transfer from the ICU. 4 The intermittent group (February 1 to July 31, 2008) included patients who received conventional intermittent dosing (piperacillin-tazobactam 3.375 g intravenously [IV] every 6 hours or meropenem 500 mg IV every 6 hours) with the 30-minute bolus infusions. The prolonged group (August 1, 2008, to January 31, 2009) included patients who received prolonged infusion (piperacillin-tazobactam 3.375 g IV every 8 hours infused over 4 hours or meropenem 500 mg IV every 6 hours infused over 3 hours). The dosing intervals are adjusted based on renal function ( Table 1 ). The piperacillintazobactam and meropenem dosing in patients with normal renal function was adopted from Lodise et al. 4 To verify the meropenem renal dosing, a Monte Carlo simulation revealed that 500 mg IV every 6 hours infused over 3 hours attained 40% f T 9 MIC for 99% of isolates with MIC of 2 or less and 92% of isolates with an MIC of 4 for patients with an estimated creatinine clearance of 40 mL/min (personal communication, G. Drusano, MD, March 24, 2008). The choice of antibiotics was decided by the prescriber based on patient history and risk factors for resistant pathogens. If a patient was admitted to this ICU more than once during a single hospital admission, only the patient's initial ICU stay was included in the study. Also, any patient whose Acute Physiology and Chronic Health Evaluation II (APACHE II) score could not be determined based on the medical record data available was excluded from the study analysis.
Data were collected from patients' medical records using a structured data collection tool to document age, sex, primary type of critical care patient (medical or surgical), APACHE II score, ICU length of stay, hospital length of stay, in-hospital mortality, patient ventilator days, duration of therapy with piperacillin-tazobactam or meropenem, and other concomitant antibiotics and their duration of therapy. Data on all cultures during the time frame of piperacillin-tazobactam or meropenem treatment (3 days before treatment initiation to 7 days after treatment discontinuation), organism susceptibility to the study agent used, and site of infection (determined from positive culture or clinical assessment) were collected. The defined daily dose (DDD) per 1000 patient days in this ICU was collected before and after implementation of prolonged infusion for both study antimicrobials. The APACHE II score was defined as the worst physiological score calculated during the initial 24 hours after admission to the ICU. Susceptibility testing was performed by in vitro Kirby-Bauer testing with zone size interpreter (BIO-MIC V3 System; Giles Scientific, Santa Barbara, Calif). 8 The main outcomes assessed in this study were assigned before study implementation and included duration of ventilator support in intubated patients, ICU length of stay, hospital length of stay, and in-hospital mortality. A pharmacoeconomic assessment of antibiotic costs was also performed and was based on the July 2009 average wholesale price of the antibiotic used.
Statistical Analysis
Multiple linear regression analysis was used to compare mean hospital length of stay, ICU length of stay, and ventilator days across study groups, adjusting for potential confounding associated with differences in underlying patient risk characteristics between study groups. The estimates for these comparisons were adjusted for age, severity of illness (APACHE II), site of infection, other antibiotics while on study therapy, and organisms recovered during treatment that were not amenable to primary therapy. Similarly, multiple logistic regression was used to analyze in-hospital death, adjusting for these potential confounders. Total hospital length of stay, ICU length of stay, and ventilator days may be nonnormal and right-skewed, thereby violating the underlying distributional assumptions of classic statistical approaches (eg, ordinary least squares). To account for possible violations of distributional assumptions, therefore, we estimated standard errors and confidence intervals (CIs) using a nonparametric bootstrapping approach with bias correction and acceleration. 9 Nonparametric bootstrapping does not rely on assumptions about the sampling distribution of the estimate and has favorable small sample properties resulting in more accurate type I error rates and greater power for identifying small effects. 10, 11 Descriptive statistical analyses were performed using SPSS (version 16.0; SPSS Inc, Chicago, Ill), and multivariate analyses were performed using Stata (version 11; StataCorp, LP, College Station, Tex). Two-sided P G 0.05 was regarded as statistically significant.
RESULTS
The 183 evaluated patients were identified through billing records as having received study medications for at least 72 hours in the ICU. Seventy-eight patients were in the intermittent group and 105 patients in the prolonged group. Evaluated patients were excluded for the following reasons: 31 were receiving continuous renal replacement therapy; 2 received both regimens; none were cystic fibrosis patients; 6 were readmitted to the ICU; in 4, we were unable to obtain their medical records; and 19 were still in the hospital at the time of study conclusion. A total of 121 patients were included in the study, with 54 in the intermittent group and 67 in the prolonged group. In the intermittent group, 18 patients (33%) received meropenem, whereas 36 patients (67%) received piperacillin-tazobactam. Thirteen patients (19%) received meropenem in the prolonged 
Estimated CrCl Dose
Piperacillin-tazobactam infused over 4 h Q20 mL/min 3.375 g IV every 8 h G20 mL/min 3.375 g IV every 12 h Hemodialysis/peritoneal dialysis 3.375 g IV every 12 h Meropenem infused over 3 h Q36 mL/min 500 mg IV every 6 h 26Y35 mL/min 500 mg IV every 8 h 10Y25 mL/min 500 mg IV every 12 h G10 mL/min 500 mg IV every 24 h Hemodialysis/peritoneal dialysis 500 mg IV every 24 h group, and 54 patients (81%) received piperacillin-tazobactam. Demographic characteristics were similar between both study groups ( Table 2 ). The average patient APACHE II scores were 25.6 T 6.8 and 24.4 T 6.5 for the intermittent infusion and the prolonged infusion patients (P = 0.237), respectively. After adjusting for confounding variables by linear regression, the intermittent group received therapy for an average total of 8.97 days compared with 9.14 days in the prolonged group ($ 0.17, 95% CI, j1.85 to 2.39). In contrast, the patients in the prolonged group had a reduced number of days of antibiotic therapy in the ICU (6.31 days) when compared with the patients in the intermittent group (7.16 days; $ j0.85; 95% CI, j2.14 to 0.28) ( Table 3 ).
In the multiple linear regression analysis of ventilated patients, time spent on the ventilator was reduced by 7.2 days (95% CI, 2.4Y12.4) in the patients receiving prolonged infusion compared with those in the intermittent group (Table 3) . A reduction in total ICU length of stay of 4.5 days (95% CI, 1.4Y8.3) as well as a reduction in the total hospital length of stay of 8.5 days (95% CI, 1.2Y18.7) was associated with the prolonged infusion group. The risk of in-hospital mortality compared between the two groups by multiple logistic regression resulted in a 12.4% mortality risk with prolonged infusion versus 20.7% with intermittent infusion (odds ratio, 0.54; 95% CI, 0.18Y1.66). Although this was not significant, the odds of dying in patients from the prolonged group were 0.54 times lower than those in the intermittent group (Table 3) .
A similar percentage of culture proven (prolonged, 45%, vs intermittent, 44%) and clinically documented (prolonged, 55%, vs intermittent, 56%) infections were found in both groups.
There were a total of 162 documented infections at multiple sites that were comparable between groups (Table 2) . Table 2 depicts the gram-negative organisms isolated from culture. Sixty-nine isolates had MICs performed to piperacillin-tazobactam and/or meropenem, with 65 isolates (94%) found to be susceptible to either agent (median MIC = 0.5; range, G0.25Y14). Sixty-four percent (44/69) of our isolates had an MIC of 1 or less to both agents. Four isolates (6%) were found to be nonsusceptible to piperacillin-tazobactam, and none of the isolates were found to be nonsusceptible to meropenem, according to the established MIC breakpoints for each antibiotic during the study period. 8 Three of these isolates (Pseudomonas aeruginosa, Enterobacter cloacae, and Escherichia coli) were from the intermittent group, whereas 1 isolate (Enterobacter aerogenes) was from the prolonged group. Patients with resistant isolates had their therapy changed to appropriate antibiotics to cover the infecting organism. Vancomycin (79%), ciprofloxacin (66%), and metronidazole (11%) were the most common concomitant antibiotics used with either piperacillin-tazobactam or meropenem, and there were no statistical differences in use between treatment groups. Twelve patients (10%) did not receive any concomitant antibiotics.
There was a decrease in the DDD per 1000 patient days of piperacillin-tazobactam in the ICU from 128.3 in the 6 months of intermittent infusion therapy to 115.4 during the first 6 months of the prolonged infusion in the ICU. There was also a decrease in the meropenem DDD per 1000 patient days from 58.6 during the intermittent infusion period to 34.5 in the prolonged infusion period.
DISCUSSION
The prolonged infusions of piperacillin-tazobactam and meropenem were adopted into clinical practice in the medical and surgical ICU after promising results in Monte Carlo simulations were followed by improved outcomes in critically ill patients. 2, 4 In this retrospective analysis of a newly implemented prolonged infusion strategy, we demonstrated significantly improved outcomes in reduced ventilator days and ICU and hospital length of stay, as well as a trend toward lower mortality with prolonged infusion. In Monte Carlo simulation, the probability of attaining 50% f T 9 MIC for the prolonged infusion of piperacillintazobactam was 92% at an MIC of 16 mg/L and 100% at MICs of less than 16 mg/L. 4 When piperacillin-tazobactam was dosed as a 30-minute bolus infusion every 6 hours, the probability of attaining 50% f T 9 MIC was greater than 90% only for an MIC of 1 mg/L. Lodise and colleagues 2 reported that critically ill patients with only P. aeruginosa infections who had APACHE II scores of 17 or greater receiving the prolonged infusion of piperacillin-tazobactam had a significantly lower 14-day mortality rate when compared with those who received the bolus intermittent infusion (12.2% vs 31.6%, respectively; P = 0.04), as well as a significantly lower median duration of hospital stay (21 vs 38 days, respectively; P = 0.02). Differences in duration of ventilation and ICU length of stay outcomes between the 2 groups were not reported. 2 Meropenem was also included in the prolonged infusion protocol based on promising but limited clinical data. A 500-mg dose of meropenem administered by prolonged infusion over 3 hours has been shown to result in mean drug exposures (%f T 9 MIC) above the MICs of 4 and 1 mg/L of 47.27% and 71.44% of the dosage interval, respectively. This was significantly greater than that obtained with a 1000-mg bolus dose at the same MICs, 42.5% and 67.04%, respectively (P G 0.05). 6 A study by Nicasio and colleagues 7 compared pharmacodynamic-based antibiotic dosing in patients treated for ventilator-associated pneumonia (VAP) with historical controls. In 21.3% of these patients, meropenem 2 g IV every 8 hours infused over 3 hours was given. The pharmacodynamic-based dosing regimens significantly decreased infection-related mortality by 13.1%, infection-related length of stay by 14.4 days, and superinfections by 19.1%. There was no difference in 28-day mortality, ICU days after VAP, ventilator duration after VAP, or total hospital length of stay for the historical versus pharmacodynamic-based dosing patients. The primary prolonged infusion A-lactam in this study was cefepime in approximately 75% of patients, which was not evaluated in our study.
The results of our study support the use of the prolonged infusions of piperacillin-tazobactam and meropenem in critically ill patients. Time spent on the ventilator, total ICU length of stay, and hospital length of stay were also significantly decreased in this study. A potential theory as to why the prolonged infusion strategy may be beneficial in critically ill patients may be due to changes in pharmacokinetics in this population. These physiological changes that can occur in these patients may lead to inadequate concentrations of A-lactam antibiotics and decreased efficacy. 12, 13 In sepsis, patients often have an increased volume of distribution due to leaky capillaries and altered protein binding, as well as an increased clearance due to an increased cardiac index. 12 The increased clearance of A-lactam antibiotics has been demonstrated in this population.
12
Hypoalbuminemia is also common in critically ill patients, resulting in lower than anticipated concentrations of drug in the blood. This can create an increase in the free drug concentration, which in turn may reduce the half-life of the drug. 13 Although a statistically significant difference in in-hospital mortality was not shown in this study, the lower risk of mortality in patients who received the prolonged infusion may represent a promising trend. We did not find a significant difference in total days of therapy or days of therapy in the ICU as a result of reliance on evidence-based guidelines for duration of therapy, such as when treating VAP. 14 We believe the large difference in ventilator days to be secondary to the above explained change in pharmacokinetics in critically ill patients, which may give the prolonged infusion strategy of A-lactams an advantage over the intermittent infusion in this population.
Relatively few studies have evaluated the clinical outcomes of the prolonged infusion of piperacillin-tazobactam and meropenem. This study is a preprotocol and postprotocol study that validates the previously reported positive outcomes in this population. 2 Although we did not demonstrate a significant difference in mortality in our patient population, several differences in our study should be discussed. First, we did not limit our study only to patients with culture-proven P. aeruginosa infections. Only 11 patients (6 in intermittent group and 5 in the prolonged group) had documented P. aeruginosa infections. Only 1 of these 11 patients, from the intermittent group, had a P. aeruginosa isolate that was reported to be resistant to piperacillin-tazobactam. In this medical and surgical ICU for 2008, 13% of all the gram-negative isolates (not just from our study) were nonsusceptible to meropenem (all P. aeruginosa), whereas 21% were nonsusceptible to piperacillin-tazobactam (Acinetobacter baumannii, E. cloacae, E. coli, Klebsiella oxytoca, Klebsiella pneumoniae, and P. aeruginosa). We included patients with both documented and suspected infections, consistent with clinical practice in patients admitted to the ICU. The patients with suspected infections had their antibiotics continued by their attending physicians secondary to clinical signs and symptoms.
The findings of our study differ from those reported by Patel and colleagues, 15 which did not observe a significant difference in 30-day mortality or median length of hospital stay by comparing patients receiving intermittent infusion to prolonged infusion piperacillin-tazobactam. Contrary to this previous study, our investigation focused solely on critical care patients, who may benefit from improved coverage with prolonged infusions due to the discussed changes in antimicrobial pharmacokinetics and pharmacodynamics that occur in this complex population. This may account for the difference in outcomes. Overall, disease severity was low in their study population. The mean APACHE II scores were only 10.5 and 10.9 for the intermittent and prolonged patients, respectively. Only 4% (intermittent group) and 7% (prolonged group) of their patients were in the ICU at the time of culture collection, and their overall mortality was much lower (intermittent group, 5%; prolonged group, 4%), as was their median hospital length of stay (8 days for both groups).
The prolonged infusion of piperacillin-tazobactam is associated with the benefit of cost savings by reducing the dosing frequency from every 6 hours to every 8 hours. Based on average wholesale price, the 54 patients who received the prolonged infusion of piperacillin-tazobactam during the 6-month period of the study, and assuming a 7-to 10-day treatment period, $8765 to $12,522 were saved by using the prolonged infusion dosing in this ICU. The reduction in the DDD for piperacillin-tazobactam was despite an increase in the actual days of use by 76 days, which reflects significant cost savings with the use of the prolonged infusion of piperacillintazobactam. In addition, our study also demonstrates cost savings due to the reduction in ventilator days and both ICU and total hospital length of stay. Based on previously published literature on the estimated cost of an ICU day, the approximate 4-day decrease in ICU length of stay in our study resulted in cost savings of $14,000 per patient in ICU stay alone. 16 The reduction in DDD for meropenem can be accounted for by a decrease in the total days of use in the ICU during this period (115 days), as the meropenem dosing regimen did not change, just the infusion time.
Several limitations of the study should be discussed. The study was retrospective in nature, and data are limited to the depth and the accuracy of the documented medical record. The study population was confined to a single-center medical/ surgical ICU. A relatively small number of patients received meropenem, which consequently makes it difficult to draw conclusions on the efficacy of prolonged infusion of meropenem individually. Patients were included with documented as well as suspected infections, and it was not limited to patients with only documented, culture-proven gram-negative infections. This may give the study improved external validity as piperacillintazobactam or meropenem is often used as empiric broadspectrum coverage in critically ill patients and then continued despite the absence of a culture-proven infection as the patient may still show clinical signs of infection. There was also a relative lack of gram-negative bacteria with high MICs during our study period. However, this is consistent with our local ICU antimicrobial susceptibility patterns over several years. Antibiotic regimens used before the initiation of piperacillin-tazobactam and meropenem were not collected. This could have influenced outcomes if patients were not treated appropriately, although only 9% of the intermittent group and 7% of the prolonged group had positive cultures drawn 48 hours or more before the initiation of study antibiotics.
The length of the study period was also limited and therefore may have had insufficient power to detect a difference in overall mortality. We do acknowledge that other threats to validity cannot be ruled out by the study design, such as regression to mean and the Hawthorne effect in the prolonged period.
In conclusion, this study shows that the use of the prolonged infusions of piperacillin-tazobactam or meropenem could potentially improve clinical and pharmacoeconomic outcomes in critically ill populations. More rigorous scientific studies in critically ill patients in a prospective manner, especially further studies with meropenem, at other institutions may support our findings and promote further implementation of this strategy.
